Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1984 Dec;50(6):757–763. doi: 10.1038/bjc.1984.253

Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer.

B A Ponder, R J Shearer, R D Pocock, J Miller, D Easton, C E Chilvers, M Dowsett, S L Jeffcoate
PMCID: PMC1977020  PMID: 6238616

Abstract

Forty patients with metastatic adenocarcinoma of the prostate were evaluated for response to treatment with aminoglutethimide plus cortisone acetate. All had relapsed from or failed to respond to primary endocrine treatment with orchidectomy or stilboestrol. Nineteen patients (48%) showed subjective response, in most cases relief of bone pain. Side effects limited treatment in only 3 patients. We conclude that aminoglutethimide plus cortisone acetate is a useful addition to the treatment available for this difficult group of patients. The mechanism by which this treatment has a beneficial effect remains unclear.

Full text

PDF
757

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Citrin D. L., Hogan T. F., Davis T. E. Chemohormonal therapy of metastatic prostate cancer. A pilot study. Cancer. 1983 Aug 1;52(3):410–414. doi: 10.1002/1097-0142(19830801)52:3<410::aid-cncr2820520305>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  2. Dexter R. N., Fishman L. M., Ney R. L., Liddle G. W. Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: studies of the mechanism of action. J Clin Endocrinol Metab. 1967 Apr;27(4):473–480. doi: 10.1210/jcem-27-4-473. [DOI] [PubMed] [Google Scholar]
  3. Dowsett M., Harris A. L., Smith I. E., Jeffcoate S. L. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. J Clin Endocrinol Metab. 1984 Jan;58(1):99–104. doi: 10.1210/jcem-58-1-99. [DOI] [PubMed] [Google Scholar]
  4. Drago J. R., Santen R. J., Lipton A., Worgul T. J., Harvey H. A., Boucher A., Manni A., Rohner T. J. Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. Cancer. 1984 Apr 1;53(7):1447–1450. doi: 10.1002/1097-0142(19840401)53:7<1447::aid-cncr2820530703>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  5. Epstein L. M., Stewart B. H., Antunez A. R., Hewitt C. B., Straffon R. A., Montague D. K., Dhaliwal R. S., Jelden G. Half and total body radiation for carcinoma of the prostate. J Urol. 1979 Sep;122(3):330–332. doi: 10.1016/s0022-5347(17)56391-0. [DOI] [PubMed] [Google Scholar]
  6. Fergusson J. D., Hendry W. F. Pituitary irradiation in advanced carcinoma of the prostate: analysis of 100 cases. Br J Urol. 1971 Oct;43(5):514–519. doi: 10.1111/j.1464-410x.1971.tb10036.x. [DOI] [PubMed] [Google Scholar]
  7. Fitzpatrick J. M., Gardiner R. A., Williams J. P., Riddle P. R., O'Donoghue E. P. Pituitary ablation in the relief of pain in advanced prostatic carcinoma. Br J Urol. 1980 Aug;52(4):301–304. doi: 10.1111/j.1464-410x.1980.tb08921.x. [DOI] [PubMed] [Google Scholar]
  8. Glick J. H., Wein A., Padavic K., Negendank W., Harris D., Brodovsky H. Phase II trial of tamoxifen in metastatic carcinoma of the prostate. Cancer. 1982 Apr 1;49(7):1367–1372. doi: 10.1002/1097-0142(19820401)49:7<1367::aid-cncr2820490711>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  9. Harris A. L., Dowsett M., Jeffcoate S. L., McKinna J. A., Morgan M., Smith I. E. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab. 1982 Oct;55(4):718–722. doi: 10.1210/jcem-55-4-718. [DOI] [PubMed] [Google Scholar]
  10. Harris A. L., Dowsett M., Jeffcoate S. L., Smith I. E. Aminoglutethimide dose and hormone suppression in advanced breast cancer. Eur J Cancer Clin Oncol. 1983 Apr;19(4):493–498. doi: 10.1016/0277-5379(83)90112-8. [DOI] [PubMed] [Google Scholar]
  11. Harris A. L., Dowsett M., Smith I. E., Jeffcoate S. L. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br J Cancer. 1983 May;47(5):621–627. doi: 10.1038/bjc.1983.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Harris A. L., Mitchell M. D., Smith I. E., Powles T. J. Suppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer. Br J Cancer. 1983 Oct;48(4):595–598. doi: 10.1038/bjc.1983.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Iqbal M. J., Johnson M. W. Study of steroid-protein binding by a novel "two-tier" column employing Cibacron Blue F3G-A-Sepharose 4B. I-Sex hormone binding globulin. J Steroid Biochem. 1977 Sep;8(9):977–983. doi: 10.1016/0022-4731(77)90196-0. [DOI] [PubMed] [Google Scholar]
  14. MILLER G. M., HINMAN F., Jr Cortisone treatment in advanced carcinoma of the prostate. J Urol. 1954 Sep;72(3):485–496. doi: 10.1016/S0022-5347(17)67614-6. [DOI] [PubMed] [Google Scholar]
  15. Mahoney E. M., Harrison J. H. Bilateral adrenalectomy for palliative treatment of prostatic cancer. J Urol. 1972 Dec;108(6):936–938. doi: 10.1016/s0022-5347(17)60911-x. [DOI] [PubMed] [Google Scholar]
  16. Moore R. J., Gazak J. M., Wilson J. D. Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17 beta-estradiol. J Clin Invest. 1979 Mar;63(3):351–357. doi: 10.1172/JCI109310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Murray F. T., Santner S., Samojlik E., Santen R. J. Serum aminoglutethimide levels: studies of serum half-life, clearance, and patient compliance. J Clin Pharmacol. 1979 Nov-Dec;19(11-12):704–711. doi: 10.1002/j.1552-4604.1979.tb01640.x. [DOI] [PubMed] [Google Scholar]
  18. Murray R. M., Pitt P., Jerums G. Medical adrenalectomy with aminoglutethimide in the management of advanced breast cancer. Med J Aust. 1981 Feb 21;1(4):179–181. doi: 10.5694/j.1326-5377.1981.tb135442.x. [DOI] [PubMed] [Google Scholar]
  19. Robinson M. R., Shearer R. J., Fergusson J. D. Adrenal suppression in the treatment of carcinoma of the prostate. Br J Urol. 1974 Oct;46(5):555–559. doi: 10.1111/j.1464-410x.1974.tb03856.x. [DOI] [PubMed] [Google Scholar]
  20. Rostom A. Y., Folkes A., Lord C., Notley R. G., Schweitzer F. A., White W. F. Aminoglutethimide therapy for advanced carcinoma of the prostate. Br J Urol. 1982 Oct;54(5):552–555. doi: 10.1111/j.1464-410x.1982.tb13589.x. [DOI] [PubMed] [Google Scholar]
  21. Sanford E. J., Drago J. R., Rohner T. J., Jr, Santen R., Lipton A. Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma. J Urol. 1976 Feb;115(2):170–174. doi: 10.1016/s0022-5347(17)59121-1. [DOI] [PubMed] [Google Scholar]
  22. Santen R. J., Santner S., Davis B., Veldhuis J., Samojlik E., Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab. 1978 Dec;47(6):1257–1265. doi: 10.1210/jcem-47-6-1257. [DOI] [PubMed] [Google Scholar]
  23. Schmidt J. D. Chemotherapy of hormone-resistant stage D prostatic cancer. J Urol. 1980 Jun;123(6):797–805. doi: 10.1016/s0022-5347(17)56140-6. [DOI] [PubMed] [Google Scholar]
  24. Schmidt J. D., Scott W. W., Gibbons R., Johnson D. E., Prout G. R., Jr, Loening S., Soloway M., deKernion J. B., Pontes J. E., Slack N. H. Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer. 1980 Apr 15;45(7 Suppl):1937–1946. [PubMed] [Google Scholar]
  25. Tindall G. T., Payne N. S., Nixon D. W. Transsphenoidal hypophysectomy for disseminated carcinoma of the prostate gland. Results in 53 patients. J Neurosurg. 1979 Mar;50(3):275–282. doi: 10.3171/jns.1979.50.3.0275. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES